<DOC>
	<DOCNO>NCT01180062</DOCNO>
	<brief_summary>This study phase 1 , open-label , dose-escalation , safety tolerability study , conduct one study site . This study include 3 cohort . Each cohort approximately 5 subject . Subjects randomize study . The first cohort receive low dose drug insert , second cohort receive 2 low dose drug insert thus achieve twice drug level compare cohort I third cohort receive high dose drug insert .</brief_summary>
	<brief_title>Safety Study Latanoprost Slow Release Insert</brief_title>
	<detailed_description>The purpose study determine tolerability safety biodegradable extend release Latanoprost subconjunctival insert primary open angle glaucoma ( POAG ) ocular hypertension ( OHT ) patient . Intraocular pressure lower ability biodegradable extend release Latanoprost subconjunctival insert POAG OHT patient also evaluate . Low dose insert initial release rate approximately 1 µg/day slow 0.2 µg/day approximately 10 day ; release rate maintain . High dose insert initial release approximately 4 µg/day , slow approximately 1 ug/day 10 day . Each drop Xalatan ( commercial form latanoprost ) contain approximately 1 µg latanoprost . The first cohort receive insert initially provide dose administer topically release rate slows low dose . The insert use study compose drug core ( Poly Lactic Glycolic acid ) PLGA polymer tube . One end tube cap impermeable polymer ( silicone ) end permeable polymer ( Polyvinyl alcohol ) . Drug release occur across permeable end function internal diameter tube . Low dose insert high dose insert exactly except low dose insert internal diameter PLGA tube small . Thus different release rate ( drug load ) obtain formulation . Inserts design provide steady state release 3-6 month .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma , Open-Angle</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Latanoprost</mesh_term>
	<criteria>Male female POAG OHT subject well control mono therapy dual therapy , undergone prior glaucoma surgery allergic nonresponders prostaglandin analogue , include study . 1 . At least 18 year old time consent . 2 . Diagnosis primary openangle glaucoma ( include pigmentary pseudoexfoliative glaucoma patient ) ocular hypertension 1 eye . 3 . IOP deem well control investigator , prostaglandin analogue/ prostanoid either monotherapy part dual medical therapy . 4 . Subjects mild moderate glaucoma subject without IOP lower treatment 2 month . 5 . Mean IOP least 22 mmHg study eye 36 mmHg either eye 8 AM baseline visit ( 4 week washout ) . 6 . Mean IOP least 20 mmHg eye qualify 8 AM 36 mmHg either eye 10 AM , 12 PM , 2 PM 4 PM baseline visit . 7 . Best Corrected Visual Acuity 20/100 good Snellen 's visual acuity measurement eye ( equivalent ETDRS Visual acuity ) . 8 . Clear ocular medium good view optic disc macula . 9 . Negative urine pregnancy test baseline woman childbearing potential . 10 . An informed consent document sign date subject legally acceptable representative . 11 . Subjects willing able comply schedule visit , treatment plan , laboratory test , study procedure 1 . Closed/barely open anterior chamber angle history acute angle closure ( i.e. , 75 % circumference angle 10° less ) either eye . 2 . Subjects diagnosis secondary glaucoma . 3 . Diagnosis clinically significant progressive retinal disease ( e.g . diabetic retinopathy , macular degeneration ) either eye would inhibit accurate VA testing . 4 . Advanced glaucoma define cup/disc ratio &gt; 0.8 history severe central visual field loss either eye . 5 . History intolerance lack response prostaglandin analogue . 6 . History hypersensitivity latanoprost ingredient study drug . 7 . Central corneal thickness great 600 μm either eye . 8 . Any condition prevents reliable applanation tonometry ( e.g . significant abnormality corneal surface ) either eye . 9 . History severe dry eye . 10 . Eye lid abnormality i.e . entropion , ectropion lower lid retraction . 11 . Evidence corneal punctate staining , exposure keratopathy keratitis , history infectious keratitis i.e . herpes . 12 . History ocular cicatricial disease i.e . cicatricial pemphigoid , pemphigus , SJ syndrome , conjunctival scar secondary topical medication . 13 . History endothelial dystrophy ( Fuchs , corneal guttata ) corneal edema . 14 . History iritis uveitis . 15 . History clinically significant aspirin intolerant asthma ( AIA ) . 16 . History ocular surgery trauma either eye within 3 month screen visit . 17 . History glaucoma filtration surgery include limited Trabeculectomy , Canaloplasty , Trabectome Glaucoma Drain surgery . 18 . History ocular infection , ocular inflammation , laser surgery either eye within 3 month screen visit . 19 . Unable discontinue contact lens use . 20 . Anticipate need initiate modify medication ( systemic topical ) know affect IOP study period . 21 . Any severe acute chronic medical psychiatric condition could increase risk associate study participation could interfere interpretation study result , judgment investigator , could make patient inappropriate entry study . 22 . Treatment investigational drug device within 30 day precede device placement . 23 . Pregnant nursing female ; female childbearing potential unwilling unable use acceptable method nonhormonal contraception outline protocol least 14 day prior first dose study medication throughout study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Latanoprost subconjunctival insert</keyword>
</DOC>